The approval of FGFR-TKI followed the recent evidence that alterations in the fibroblast growth factor receptor 3 (FGFR3) gene are common in non-invasive bladder cancer and can be used to identify patients who may benefit from targeted therapy [1, 7-9]. Here, FGFR3 is linked to urinary bladder carcinoma.